Antibodies against anthrax: Mechanisms of action and clinical applications

Toxins

Volumn 3, Issue 11, 2011, Pages 1433-1452

  Froude II, Jeffrey W ^a,b   Thullier, Philippe ^a   Pelat, Thibaut ^a  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^b U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

Author keywords

Anthrax toxins; Antibodies; Edema factor; Lethal factor; Protective antigen

Indexed keywords

ANTHRAX ANTIBODY; ANTHRAX TOXIN; EDEMA FACTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F26G3; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL MEMBRANE; DRUG MECHANISM; HUMAN; LETHAL GENE; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; HUMANS;

EID: 82255165398     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins3111433     Document Type: Review

References (88)

1. Inglesby, T.V.; O'Toole, T.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Friedlander, A.M.; Gerberding, J.; Hauer, J.; Hughes, J. et al. Anthrax as a biological weapon, 2002: Updated recommendations for management. J. Am. Med. Assoc. 2002, 287, 2236-2252.
2. Green, B.D.; Battisti, L.; Koehler, T.M.; Thorne, C.B.; Ivins, B.E. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun. 1985, 49, 291-297.
3. Friedlander, A.M. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 1986, 261, 7123-7126.
4. Barth, H.; Aktories, K.; Popoff, M.R.; Stiles, B.G. Binary bacterial toxins: Biochemistry, biology, and applications of common clostridium and bacillus proteins. Microbiol. Mol. Biol. Rev. 2004, 68, 373-402.
5. Collier, R.J.; Young, J.A. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 2003, 19, 45-70.
6. Petosa, C.; Collier, R.J.; Klimpel, K.R.; Leppla, S.H.; Liddington, R.C. Crystal structure of the anthrax toxin protective antigen. Nature 1997, 385, 833-838.
7. Pannifer, A.D.; Wong, T.Y.; Schwarzenbacher, R.; Renatus, M.; Petosa, C.; Bienkowska, J. Lacy, D.B.; Collier, R.J.; Park, S.; Leppla, S.H.; et al. Crystal structure of the anthrax lethal factor. Nature 2001, 414, 229-233.
8. Drum, C.L.; Yan, S.Z.; Bard, J.; Shen, Y.Q.; Lu, D.; Soelaiman, S.; Grabarek, Z.; Bohm, A.; Tang, W.J. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature 2002, 415, 396-402.
9. Lacy, D.B.; Wigelsworth, D.J.; Melnyk, R.A.; Harrison, S.C.; Collier, R.J. Structure of heptameric protective antigen bound to an anthrax toxin receptor: A role for receptor in pH-dependent pore formation. Proc. Natl. Acad. Sci. USA 2004, 101, 13147-13151.
10. Santelli, E.; Bankston, L.A.; Leppla, S.H.; Liddington, R.C. Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature 2004, 430, 905-908.
11. Mogridge, J.; Mourez, M.; Collier, R.J. Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin. J. Bacteriol. 2001, 183, 2111-2116.
12. Little, S.F.; Lowe, J.R. Location of receptor-binding region of protective antigen from Bacillus anthracis. Biochem. Biophys. Res. Commun. 1991, 180, 531-537.
13. Rosovitz, M.J.; Schuck, P.; Varughese, M.; Chopra, A.P.; Mehra, V.; Singh, Y.; McGinnis, L.M.; Leppla, S.H. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J. Biol. Chem. 2003, 278, 30936-30944.
14. Bradley, K.A.; Mogridge, J.; Mourez, M.; Collier, R.J.; Young, J.A. Identification of the cellular receptor for anthrax toxin. Nature 2001, 414, 225-229.
15. Scobie, H.M.; Rainey, G.J.; Bradley, K.A.; Young, J.A. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 2003, 100, 5170-5174.
16. Vitale, G.; Bernardi, L.; Napolitani, G.; Mock, M.; Montecucco, C. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 2000, 352, 739-745.
17. Duesbery, N.S.; Webb, C.P.; Leppla, S.H.; Gordon, V.M.; Klimpel, K.R.; Copeland, T.D.; Ahn, N.G.; Oskarsson, M.K.; Fukasawa, K.; Paull, K.D.; et al. Proteolytic inactivation of map-kinase-kinase by anthrax lethal factor. Science 1998, 280, 734-737.
18. Leppla, S.H. Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic amp concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 1982, 79, 3162-3166.
19. Leppla, S.H.; Arora, N.; Varughese, M. Anthrax toxin fusion proteins for intracellular delivery of macromolecules. J. Appl. Microbiol. 1999, 87, 284.
20. Quinn, C.P.; Singh, Y.; Klimpel, K.R.; Leppla, S.H. Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis. J. Biol. Chem. 1991, 266, 20124-20130.
21. Legge, T.M. The milroy lectures on industrial anthrax: Delivered before the royal college of physicians of london. Br. Med. J. 1905, 1, 641-643.
22. Meyerhoff, A.; Albrecht, R.; Meyer, J.M.; Dionne, P.; Higgins, K.; Murphy, D. US food and drug administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. Clin. Infect. Dis. 2004, 39, 303-308.
23. FDA. Prescription drug product: Doxycycline and penicillin g procaine administration for inhalational anthrax (post-exposure). Fed. Regist. 2001, 55679-55682.
24. Shepard, C.W.; Soriano-Gabarro, M.; Zell, E.R.; Hayslett, J.; Lukacs, S.; Goldstein, S.; Factor, S.; Jones, J.; Ridzon, R.; Williams, I.; et al. Antimicrobial postexposure prophylaxis for anthrax: Adverse events and adherence. Emerg. Infect. Dis. 2002, 8, 1124-1132.
25. CDC, Update: Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. MMWR Morb. Mortal. Wkly. Rep. 2001, 50, 973-976.
26. Beharry, Z.; Chen, H.; Gadhachanda, V.R.; Buynak, J.D.; Palzkill, T. Evaluation of penicillin-based inhibitors of the class a and b beta-lactamases from Bacillus anthracis. Biochem. Biophys. Res. Commun. 2004, 313, 541-545.
27. Chen, Y.; Tenover, F.C.; Koehler, T.M. Beta-lactamase gene expression in a penicillin-resistant Bacillus anthracis strain. Antimicrob. Agents Chemother. 2004, 48, 4873-4877.
28. Athamna, A.; Athamna, M.; Abu-Rashed, N.; Medlej, B.; Bast, D.J.; Rubinstein, E. Selection of Bacillus anthracis isolates resistant to antibiotics. J. Antimicrob. Chemother. 2004, 54, 424-428.
29. Price, L.B.; Vogler, A.; Pearson, T.; Busch, J.D.; Schupp, J.M.; Keim, P. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob. Agents Chemother. 2003, 47, 2362-2365.
30. Choe, C.H.; Bouhaouala, S.S.; Brook, I.; Elliot, T.B.; Knudson, G.B. In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis sterne. Antimicrob. Agents Chemother. 2000, 44, doi:10.1128/AAC.44.6.1766-1766.2000.
31. Albrecht, M.T.; Li, H.; Williamson, E.D.; LeButt, C.S.; Flick-Smith, H.C.; Quinn, C.P.; Westra, H.; Galloway, D.; Mateczun, A.; Goldman, S.; et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun. 2007, 75, 5425-5433.
32. Wigelsworth, D.J.; Krantz, B.A.; Christensen, K.A.; Lacy, D.B.; Juris, S.J.; Collier, R.J. Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, cmg2, with protective antigen. J. Biol. Chem. 2004, 279, 23349-23356.
33. Lacy, D.B.; Wigelsworth, D.J.; Scobie, H.M.; Young, J.A.; Collier, R.J. Crystal structure of the von willebrand factor a domain of human capillary morphogenesis protein 2: An anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 2004, 101, 6367-6372.
34. Bradley, K.A.; Mogridge, J.; Jonah, G.; Rainey, A.; Batty, S.; Young, J.A. Binding of anthrax toxin to its receptor is similar to alpha integrin-ligand interactions. J. Biol. Chem. 2003, 278, 49342-49347.
35. Little, S.F.; Leppla, S.H.; Cora, E. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 1988, 56, 1807-1813.
36. Laffly, E.; Danjou, L.; Condemine, F.; Vidal, D.; Drouet, E.; Lefranc, M.P.; Bottex, C.; Thullier, P. Selection of a macaque fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (pa) of Bacillus anthracis by binding to the segment of pa between residues 686 and 694. Antimicrob. Agents Chemother. 2005, 49, 3414-3420.
37. Kelly-Cirino, C.D.; Mantis, N.J. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect. Immun. 2009, 77, 4859-4867.
38. Chen, Z.; Moayeri, M.; Zhou, Y.H.; Leppla, S.; Emerson, S.; Sebrell, A.; Yu, F.; Svitel, J.; Schuck, P.; St Claire, M.; et al. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J. Infect. Dis. 2006, 193, 625-633.
39. Brossier, F.; Levy, M.; Landier, A.; Lafaye, P.; Mock, M. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun. 2004, 72, 6313-6317.
40. Zhou, B.; Carney, C.; Janda, K.D. Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin. Bioorg. Med. Chem. 2008, 16, 1903-1913.
41. Mazumdar, S. Raxibacumab. MAbs 2009, 1, 531-538.
42. Wild, M.A.; Xin, H.; Maruyama, T.; Nolan, M.J.; Calveley, P.M.; Malone, J.D.; Wallace, M.R. Bowdish, K.S. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat, Biotechnol. 2003, 21, 1305-1306.
43. Migone, T.S.; Subramanian, G.M.; Zhong, J.; Healey, L.M.; Corey, A.; Devalaraja, M.; Lo, L.; Ullrich, S.; Zimmerman, J.; Chen, A. et al. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med. 2009, 361, 135-144.
44. Antoniu, S.A. Raxibacumab for inhalational anthrax: An effective specific therapeutic approach? Expert Opin. Investig. Drugs 2010, 19, 909-911.
45. Mohamed, N.; Clagett, M.; Li, J.; Jones, S.; Pincus, S.; D'Alia, G.; Nardone, L.; Babin, M.; Spitalny, G.; Casey, L. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. 2005, 73, 795-802.
46. Klimpel, K.R.; Molloy, S.S.; Thomas, G.; Leppla, S.H. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. USA 1992, 89, 10277-10281.
47. Singh, Y.; Chaudhary, V.K.; Leppla, S.H. A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J. Biol. Chem. 1989, 264, 19103-19107.
48. Christensen, K.A.; Krantz, B.A.; Melnyk, R.A.; Collier, R.J. Interaction of the 20 kda and 63 kda fragments of anthrax protective antigen: Kinetics and thermodynamics. Biochemistry 2005, 44, 1047-1053.
49. Rivera, J.; Nakouzi, A.; Abboud, N.; Revskaya, E.; Goldman, D.; Collier, R.J.; Dadachova, E.; Casadevall, A. A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect. Immun. 2006, 74, 4149-4156.
50. Wang, F.; Ruther, P.; Jiang, I.; Sawada-Hirai, R.; Sun, S.M.; Nedellec, R.; Morrow, P.R.; Kang, A.S. Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly. Hum. Antib. 2004, 13, 105-110.
51. Milne, J.C.; Furlong, D.; Hanna, P.C.; Wall, J.S.; Collier, R.J. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 1994, 269, 20607-20612.
52. Little, S.F.; Novak, J.M.; Lowe, J.R.; Leppla, S.H.; Singh, Y.; Klimpel, K.R.; Lidgerding, B.C.; Friedlander, A.M. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 1996, 142, 707-715.
53. Peterson, J.W.; Comer, J.E.; Baze, W.B.; Noffsinger, D.M.; Wenglikowski, A.; Walberg, K.G.; Hardcastle, J.; Pawlik, J.; Bush, K.; Taormina, J.; et al. Human monoclonal antibody avp-21d9 to protective antigen reduces dissemination of the Bacillus anthracis ames strain from the lungs in a rabbit model. Infect. Immun. 2007, 75, 3414-3424.
54. Vitale, L.; Blanset, D.; Lowy, I.; O'Neill, T.; Goldstein, J.; Little, S.F.; Andrews, G.P.; Dorough, G.; Taylor, R.K.; Keler, T. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect. Immun. 2006, 74, 5840-5847.
55. Radjainia, M.; Hyun, J.K.; Leysath, C.E.; Leppla, S.H.; Mitra, A.K. Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex. Proc. Natl. Acad. Sci. USA 2010, 107, 14070-14074.
56. Elliott, J.L.; Mogridge, J.; Collier, R.J. A quantitative study of the interactions of Bacillus anthracis edema factor and lethal factor with activated protective antigen. Biochemistry 2000, 39, 6706-6713.
57. Feld, G.K.; Thoren, K.L.; Kintzer, A.F.; Sterling, H.J.; Tang, I.I.; Greenberg, S.G.; Williams, E.R.; Krantz, B.A. Structural basis for the unfolding of anthrax lethal factor by protective antigen oligomers. Nat. Struct. Mol. Biol. 2010, 17, 1383-1390.
58. Kintzer, A.F.; Thoren, K.L.; Sterling, H.J.; Dong, K.C.; Feld, G.K.; Tang, I.I.; Zhang, T.T.; Williams, E.R.; Berger, J.M.; Krantz, B.A. The protective antigen component of anthrax toxin forms functional octameric complexes. J. Mol. Biol. 2009, 392, 614-629.
59. Cunningham, K.; Lacy, D.B.; Mogridge, J.; Collier, R.J. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. Proc. Natl. Acad. Sci. USA 2002, 99, 7049-7053.
60. Kumar, P.; Ahuja, N.; Bhatnagar, R. Purification of anthrax edema factor from Escherichia coli and identification of residues required for binding to anthrax protective antigen. Infect. Immun. 2001, 69, 6532-6536.
61. Lacy, D.B.; Lin, H.C.; Melnyk, R.A.; Schueler-Furman, O.; Reither, L.; Cunningham, K.; Baker, D.; Collier, R.J. A model of anthrax toxin lethal factor bound to protective antigen. Proc. Natl. Acad. Sci. USA 2005, 102, 16409-16414.
62. Lacy, D.B.; Mourez, M.; Fouassier, A.; Collier, R.J. Mapping the anthrax protective antigen binding site on the lethal and edema factors. J. Biol. Chem. 2002, 277, 3006-3010.
63. Melnyk, R.A.; Hewitt, K.M.; Lacy, D.B.; Lin, H.C.; Gessner, C.R.; Li, S.; Woods, V.L., Jr.; Collier, R.J. Structural determinants for the binding of anthrax lethal factor to oligomeric protective antigen. J. Biol. Chem. 2006, 281, 1630-1635.
64. Steiniger, S.C.; Altobell, L.J., III; Zhou, B.; Janda, K.D. Selection of human antibodies against cell surface-associated oligomeric anthrax protective antigen. Mol. Immunol. 2007, 44, 2749-2755.
65. Price, B.M.; Liner, A.L.; Park, S.; Leppla, S.H.; Mateczun, A.; Galloway, D.R. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 2001, 69, 4509-4515.
66. Zhao, P.; Liang, X.; Kalbfleisch, J.; Koo, H.M.; Cao, B. Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum. Antib. 2003, 12, 129-135.
67. Nguyen, M.L.; Crowe, S.R.; Kurella, S.; Teryzan, S.; Cao, B.; Ballard, J.D.; James, J.A.; Farris, A.D. Sequential b-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect. Immun. 2009, 77, 162-169.
68. Little, S.F.; Leppla, S.H.; Friedlander, A.M. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect. Immun. 1990, 58, 1606-1613.
69. Lim, N.K.; Kim, J.H.; Oh, M.S.; Lee, S.; Kim, S.Y.; Kim, K.S.; Kang, H.J.; Hong, H.J.; Inn, K.S. An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect. Immun. 2005, 73, 6547-6551.
70. Pelat, T.; Hust, M.; Laffly, E.; Condemine, F.; Bottex, C.; Vidal, D.; Lefranc, M.P.; Dubel, S.; Thullier, P. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (lf) of Bacillus anthracis by inhibiting protective antigen-lf complex formation. Antimicrob. Agents Chemother. 2007, 51, 2758-2764.
71. Kulshreshtha, P.; Bhatnagar, R. Inhibition of anthrax toxins with a bispecific monoclonal antibody that cross reacts with edema factor as well as lethal factor of Bacillus anthracis. Mol. Immunol. 2011, doi:10.1016/j.molimm.2011.1005.1024.
72. Little, S.F.; Leppla, S.H.; Burnett, J.W.; Friedlander, A.M. Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies. Biochem. Biophys. Res. Commun. 1994, 199, 676-682.
73. Abrami, L.; Liu, S.; Cosson, P.; Leppla, S.H.; van der Goot, F.G. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J. Cell Biol. 2003, 160, 321-328.
74. Abrami, L.; Lindsay, M.; Parton, R.G.; Leppla, S.H.; van der Goot, F.G. Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway. J. Cell Biol. 2004, 166, 645-651.
75. Chen, Z.; Moayeri, M.; Crown, D.; Emerson, S.; Gorshkova, I.; Schuck, P.; Leppla, S.H.; Purcell, R.H. Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect. Immun. 2009, 77, 3902-3908.
76. Chen, Z.; Moayeri, M.; Zhao, H.; Crown, D.; Leppla, S.H.; Purcell, R.H. Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proc. Natl. Acad. Sci. USA 2009, 106, 13487-13492.
77. Ivins, B.E.; Welkos, S.L. Cloning and expression of the Bacillus anthracis protective antigen gene in bacillus subtilis. Infect. Immun. 1986, 54, 537-542.
78. Drysdale, M.; Heninger, S.; Hutt, J.; Chen, Y.; Lyons, C.R.; Koehler, T.M. Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax. Embo J. 2005, 24, 221-227.
79. Wang, T.T.; Fellows, P.F.; Leighton, T.J.; Lucas, A.H. Induction of opsonic antibodies to the gamma-d-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS Immunol. Med. Microbiol. 2004, 40, 231-237.
80. Kozel, T.R.; Murphy, W.J.; Brandt, S.; Blazar, B.R.; Lovchik, J.A.; Thorkildson, P.; Percival, A.; Lyons, C.R. Mabs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc. Natl. Acad. Sci. USA 2004, 101, 5042-5047.
81. Kozel, T.R.; Thorkildson, P.; Brandt, S.; Welch, W.H.; Lovchik, J.A.; AuCoin, D.P.; Vilai, J.; Lyons, C.R. Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect. Immun. 2007, 75, 152-163.
82. Chen, Z.; Schneerson, R.; Lovchik, J.; Lyons, C.R.; Zhao, H.; Dai, Z.; Kubler-Kielb, J.; Leppla, S.H.; Purcell, R.H. Pre-and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule. Proc. Natl. Acad. Sci. USA 2011, 108, 739-744.
83. Tirado, S.M.; Yoon, K.J. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 2003, 16, 69-86.
84. Mohamed, N.; Li, J.; Ferreira, C.S.; Little, S.F.; Friedlander, A.M.; Spitalny, G.L.; Casey, L.S. Enhancement of anthrax lethal toxin cytotoxicity: A subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect. Immun. 2004, 72, 3276-3283.
85. Little, S.F.; Webster, W.M.; Fisher, D.E. Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo. FEMS Immunol. Med. Microbiol. 2011, 62, 11-22.
86. Pelat, T.; Hüst, M.; Laffly, E.; Condemine, F.; Bottex, C.; Vidal, D.; Lefranc, M.P.; Dübel, S.; Thullier, P. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (lf) of Bacillus anthracis by inhibiting protective antigen-lf complex formation. Antimicrob. Agents Chemother. 2007, 51, 2758-2764.
87. Adekar, S.P.; Takahashi, T.; Jones, R.M.; Al-Saleem, F.H.; Ancharski, D.M.; Root, M.J.; Kapadnis, B.P.; Simpson, L.L.; Dessain, S.K. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One 2008, 3, doi:10.1371/journal.pone.0003023.
88. Baillie, L.W. Past, imminent and future human medical countermeasures for anthrax. J. Appl. Microbiol. 2006, 101, 594-606.